ENGNNasdaq

ENGENE HOLDINGS INC.

Healthcare·Oncology·Commercial·Montreal, QC, Canada
OncologyRare DiseaseRespiratoryGastroenterology

ENGENE HOLDINGS INC. (ENGN): 5 pipeline candidates · 1 upcoming catalyst · ~28 mo cash runway. Updated within the last hour.

8.0/10

BioSniper Score

5-factor signal · derived from public data

Cash Runway7.7

27.8 months

Financial Health9.7

D/E 0.20 · 0% dilution

Pipeline Maturity10.0

Lead: Approved

Pipeline Breadth8.5

5 candidates

Catalyst Momentum4.0

1 upcoming, next in ~30d

Insider SignalN/A

N/A

A transparent, data-derived signal for ENGENE HOLDINGS INC.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.

Key Financials

Market Cap

$117.6M

Cash

$36.6M

Quarterly Burn

$28.9M

Runway

27.8 mo

Revenue

—

Cash Runway vs Catalysts

Tracked catalysts land within the current projected cash runway.

Cash ends ~Oct 2028
Today~31 mo out
Catalyst within runway

Pipeline (5 candidates)

DrugPhase
acetylcysteineApproved
detalimogenePhase 2
detalimogene voraplasmidPhase 2
eg-i08Preclinical
famotidineApproved

Upcoming Catalysts (1)

Patent_ExpiryPatent/Exclusivity Expiry: DUEXIS

Loss of exclusivity — patent/exclusivity expiry opens the door to generic or biosimilar competition that can erode revenue.

Institutional Holdings

Source: SEC Form 13F · as of Mar 2026

Institutional holders

2

Total value held

$2.3M

HolderSharesValue
marshall wace, llp343,928$2.3M
sbi securities co., ltd.28$191
·1 FDA decision·CEO: Mr. Ronald H. W. Cooper

Frequently asked questions

How many drug candidates are in ENGENE HOLDINGS INC.'s pipeline?

ENGENE HOLDINGS INC. (ENGN) has 5 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.

What is ENGENE HOLDINGS INC.'s lead drug candidate?

ENGENE HOLDINGS INC.'s most advanced tracked candidate is acetylcysteine (Approved) for 1 INDICATIONS & USAGE Acetylcysteine injection is indicated to prevent or lessen hepatic injury after ingestion of a potentially hepatotoxic quantity of acetaminophen in patients with acute ingestion or from repeated supratherapeutic ingestion (RSI). Acetylcysteine injection is an antidote for acetaminophen overdose indicated to prevent or lessen hepatic injury after ingestion of a potentially hepatotoxic quantity of acetaminophen in patients with an acute ingestion or from repeated supratherape.

What is ENGENE HOLDINGS INC.'s next catalyst?

ENGENE HOLDINGS INC.'s next tracked catalyst is a Patent_Expiry event — "Patent/Exclusivity Expiry: DUEXIS" — expected July 18, 2026.

What is ENGENE HOLDINGS INC.'s cash runway?

Based on its most recent reported cash balance and quarterly burn rate, ENGENE HOLDINGS INC. has approximately 27.8 months of cash runway.

What is ENGENE HOLDINGS INC.'s market capitalization?

ENGENE HOLDINGS INC.'s market capitalization is approximately $117.6M.

Get the full picture on ENGENE HOLDINGS INC.

Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.

Start Free AnalysisBrowse Calendar